News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
756,496 Results
Type
Article (48684)
Company Profile (275)
Press Release (707527)
Multimedia
Podcasts (89)
Webinars (17)
Section
Business (212910)
Career Advice (2066)
Deals (36746)
Drug Delivery (116)
Drug Development (83383)
Employer Resources (174)
FDA (16790)
Job Trends (15227)
News (358923)
Policy (33899)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2613)
Accelerated approval (31)
Adcomms (25)
Allergies (143)
Alliances (52448)
ALS (171)
Alzheimer's disease (1675)
Antibody-drug conjugate (ADC) (318)
Approvals (17053)
Artificial intelligence (514)
Autoimmune disease (154)
Automation (37)
Bankruptcy (370)
Best Places to Work (11704)
BIOSECURE Act (20)
Biosimilars (188)
Biotechnology (179)
Bladder cancer (159)
Brain cancer (56)
Breast cancer (638)
Cancer (4814)
Cardiovascular disease (410)
Career advice (1744)
Career pathing (36)
CAR-T (287)
CDC (45)
Celiac Disease (2)
Cell therapy (748)
Cervical cancer (36)
Clinical research (71072)
Collaboration (1718)
Company closure (4)
Compensation (1138)
Complete response letters (54)
COVID-19 (2764)
CRISPR (90)
C-suite (825)
Cystic fibrosis (143)
Data (6201)
Decentralized trials (2)
Denatured (25)
Depression (134)
Diabetes (503)
Diagnostics (6739)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (250)
Drug pricing (190)
Drug shortages (29)
Duchenne muscular dystrophy (225)
Earnings (90728)
Editorial (55)
Employer branding (21)
Employer resources (152)
Events (124053)
Executive appointments (974)
FDA (19892)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1479)
Gene editing (196)
Generative AI (42)
Gene therapy (601)
GLP-1 (991)
Government (4728)
Grass and pollen (7)
Guidances (384)
Healthcare (19069)
HIV (55)
Huntington's disease (46)
IgA nephropathy (83)
Immunology and inflammation (261)
Immuno-oncology (56)
Indications (103)
Infectious disease (3027)
Inflammatory bowel disease (193)
Inflation Reduction Act (14)
Influenza (111)
Intellectual property (245)
Interviews (324)
IPO (16860)
IRA (49)
Job creations (3864)
Job search strategy (1459)
JPM (58)
Kidney cancer (15)
Labor market (84)
Layoffs (562)
Leadership (30)
Legal (8295)
Liver cancer (95)
Longevity (14)
Lung cancer (643)
Lymphoma (380)
Machine learning (42)
Management (60)
Manufacturing (788)
MASH (164)
Medical device (13846)
Medtech (13898)
Mergers & acquisitions (20946)
Metabolic disorders (1284)
Multiple sclerosis (158)
NASH (16)
Neurodegenerative disease (317)
Neuropsychiatric disorders (87)
Neuroscience (2905)
Neurotech (1)
NextGen: Class of 2026 (6668)
Non-profit (4545)
Now hiring (65)
Obesity (606)
Opinion (289)
Ovarian cancer (167)
Pain (200)
Pancreatic cancer (223)
Parkinson's disease (283)
Partnered (33)
Patents (489)
Patient recruitment (478)
Peanut (58)
People (62708)
Pharmaceutical (63)
Pharmacy benefit managers (29)
Phase 1 (22202)
Phase 2 (31254)
Phase 3 (23200)
Pipeline (5113)
Policy (281)
Postmarket research (2717)
Preclinical (9455)
Press Release (65)
Prostate cancer (236)
Psychedelics (48)
Radiopharmaceuticals (281)
Rare diseases (835)
Real estate (6301)
Recruiting (69)
Regulatory (25229)
Reports (51)
Research institute (2407)
Resumes & cover letters (357)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (149)
Series A (247)
Series B (198)
Service/supplier (11)
Sickle cell disease (97)
Special edition (21)
Spinal muscular atrophy (161)
Sponsored (41)
Startups (3927)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (87)
The Weekly (62)
Vaccines (1009)
Venture capital (91)
Weight loss (395)
Women's health (87)
Worklife (18)
Date
Last 7 days (602)
Last 30 days (1980)
Last 365 days (30086)
2026 (2861)
2025 (30532)
2024 (35581)
2023 (40468)
2022 (51590)
2021 (56124)
2020 (54486)
2019 (46992)
2018 (35413)
2017 (33477)
2016 (33894)
2015 (40432)
2014 (34067)
2013 (29469)
2012 (31526)
2011 (31888)
2010 (30166)
Location
Africa (817)
Alabama (83)
Alaska (7)
Arizona (318)
Arkansas (13)
Asia (42803)
Australia (7008)
California (11211)
Canada (3261)
China (1115)
Colorado (475)
Connecticut (471)
Delaware (332)
Europe (93748)
Florida (1664)
Georgia (354)
Hawaii (3)
Idaho (62)
Illinois (871)
India (63)
Indiana (513)
Iowa (22)
Japan (421)
Kansas (127)
Kentucky (39)
Louisiana (26)
Maine (72)
Maryland (1375)
Massachusetts (8055)
Michigan (321)
Minnesota (624)
Mississippi (5)
Missouri (125)
Montana (33)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2976)
New Mexico (28)
New York (2963)
North Carolina (1454)
North Dakota (8)
Northern California (5464)
Ohio (332)
Oklahoma (21)
Oregon (42)
Pennsylvania (2265)
Puerto Rico (22)
Rhode Island (47)
South America (1227)
South Carolina (65)
South Dakota (1)
Southern California (4357)
Tennessee (173)
Texas (1726)
United States (39808)
Utah (333)
Vermont (1)
Virginia (261)
Washington D.C. (82)
Washington State (916)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
756,496 Results for "b temia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
January 13, 2026
·
7 min read
Press Releases
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 24, 2025
·
4 min read
Press Releases
B. Braun Medical Inc. Launches Piperacillin and Tazobactam for Injection and Sodium Chloride Injection in the DUPLEX® Drug Delivery System
December 8, 2025
·
3 min read
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
The alliance will add to Roche’s RNAi efforts, which include the hypertension candidate zilbesiran, partnered with Alnylam under a July 2023 agreement.
February 3, 2026
·
1 min read
·
Tristan Manalac
Manufacturing
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.
January 21, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Magnet Biomedicine Expands Leadership with Appointment of Nick Vlahakis, M.B.B.S., as Chief Medical Officer
January 13, 2026
·
3 min read
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions
AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.
January 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
January 5, 2026
·
9 min read
1 of 75,650
Next
